Travere Therapeutics Inc. (TVTX)
TVTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$51.80
-0.42% on the day
Market cap
$4.9B
Mid cap
Revenue · 2025
$490.7M
+110.5% on 2024
Net income · 2025
-$25.5M
-5.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TVTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001438533 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | CA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $490.7M |
| Net income | -$25.5M |
| Operating income | -$62.8M |
| Net margin | -5.2% |
| Operating margin | -12.8% |
| Revenue growth | +110.5% |
| Cash | $93.0M |
| Total assets | $605.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -14.8% |
| 3 months | -3.7% |
| Year to date | +39.3% |
| 1 year | +103.2% |
| From 52-week high | -21.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COGT | Cogent Biosciences Inc. | $28.09 | -5.67% | $4.9B |
| MANE | Veradermics Incorporated | $116.26 | -5.02% | $4.9B |
| GRFS | Grifols S.A. | $7.17 | -2.71% | $4.9B |
| PTCT | PTC Therapeutics Inc. | $59.92 | -4.77% | $5.0B |
| ERAS | Erasca Inc. | $14.78 | -4.40% | $5.2B |
| MIRM | Mirum Pharmaceuticals Inc. | $79.62 | -7.48% | $5.2B |
| DNTH | Dianthus Therapeutics Inc. | $77.58 | -4.89% | $4.3B |
| INDV | Indivior Pharmaceuticals Inc. | $35.42 | -1.77% | $4.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier